References
- Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL, Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transpl. 2000;14:97–109.
- MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000;(22 suppl B):B101–21.
- Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24:330–50.
- Mabasa VH, Enson MHH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit. 2005;27:666–76.
- Kovarik JM, Tedesco H, Pascual J, Civati G, Bizot MN, Geissler J, Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26:499–505.
- Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40:573–85.
- Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;a43:83–95.
- Rapamune®. Guía práctica para uso clínico. Madrid; Wyeth Pharmaceuticals España.
- Bouzas L, Hermida J, Tutor JC. Determination of blood sirolimus concentrations in liver and kidney transplant recipients using the Innofluor® fluorescence polarization immunoassay: comparison with the microparticle enzyme immunoassay and high-performance liquid chromatography-ultraviolet method. Upsala J Med Sci. 2009;114:55–61.
- Bouzas L, Tutor JC. Determination of everolimus in whole blood using the Abbott IMx sirolimus microparticle enzyme immunoassay. Clin Biochem. 2007;40:132–6.
- Winter ME. Basic Clinical Pharmacokinetics. 4th ed. Philadelphia; Lippincot Williams and Wilkins; 2004.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:87–94.
- Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Analytical methods validation: bioavalability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16:249–55.
- Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, Bioanalytical method validation––a revisit with a decade of progress. Pharm Res. 2000;17:1551–7.
- Kuypers DR. Influence of interactions betwen immunosuppressive drugs on therapeutic drug monitoring. Ann Transpl. 2008;13:11–18.
- Zimmerman JJ, Lasseter KC, Lim HK, Harper D, Dilzer SC, Parker V, Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45:1368–72.
- Zimmerman JJ, Patat A, Parks V, Moirand R, Matschke K. Pharmacokinetics of sirolimus (rapamycin) in subjects with severe hepatic impairment. J Clin Pharmacol. 2008;48:285–92.
- Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther. 2001;70:425–30.
- Dreisbach AW, Lertora JJL. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Metab Toxicol. 2008;4:1065–74.
- Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83:898–903.
- Shastri YM, Hopffner NM, Akoglu B, Zapletal C, Bechstein WO, Liver biochemistry profile, significance and endoscopic management of biliary tract complications post orthotopic liver transplantation. World Gastroenterol. 2007;13:2819–25.
- Zahir H, Keogh A, Akhlagi F. Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. Ther Drug Monit. 2006;28:818–26.
- Gornall AG. Basic concepts in laboratory investigation. In: Gornall AG, editor. Applied biochemistry of clinical disorders. 2nd ed. Philadelphia; JB Lippincott Company; 1986. p. 3 –13.